Lundbeck Abandons Alzheimer's Med

Feb 09, 2017

Reuters

After two failed late-stage clinical trials, Lundbeck has called it quits on its experimental Alzheimer's drug.

The Denmark-based drugmaker said the trials for its idalopirdine "do not demonstrate efficacy to support a regulatory submission."

The 5-HT6 antagonist was aimed at treating symptoms of the brain disorder, rather than halting progression of the underlying disease. U.S.-based rival Axovant Sciences is developing similar 5-HT6 antagonist drug called intepirdine.

Read the Reuters coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments